Sheetal Decaria, MD
Interventional Pain Medicine · Glenview, ILNPI 1649569534
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,800 of the $6,679 with a category attached, or 86.8%. Baxter Healthcare accounts for 86.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $3,009 and has fallen 89.9% since, to $303 in 2025.
Across 29 payments — averaging $230.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$6K
- AbbVie$326
- Stratus Medical, LLC$143
- Centinel Spine, LLC$104
- Avanos Medical$79
- Spinefrontier, Inc.$55
- plus $171 from 5 others
What the payments were for
- Consulting fees$5,80087%
- Food & beverage$87913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 2 | $5,800 |
| AbbVie(2 entities) | 14 | $326 |
| Stratus Medical, LLC | 2 | $143 |
| Centinel Spine, LLC | 1 | $104 |
| Avanos Medical | 1 | $79 |
| Spinefrontier, Inc. | 1 | $55 |
| Abbott | 1 | $48 |
| Fidia Pharma USA Inc. | 4 | $47 |
| Pacira Pharmaceuticals Incorporated | 1 | $44 |
| Novo Nordisk | 1 | $21 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fluid Systems - Infusion Systems$5,800
- Nimbus$113
- PRODISC L$104
How this compares
$6,679 in reported general payments places this provider in the 70th percentile of 93 interventional pain medicine providers in Illinois.
See all interventional pain medicine providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 155 | $1,143 |
| Duloxetine Hcl | 19 | $164 |
| Baclofen | 19 | $102 |
| Cyclobenzaprine Hcl | 14 | $74 |
| Pregabalin | 21 | $63 |
| Diclofenac Sodium | 12 | $49 |
| Meloxicam | 20 | $48 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Glenview
- Alexander FeoktistovNorthfield$922K
- Timothy LubenowChicago$556K
- Sandeep AminChicago$430K
- Matthew JaycoxChicago$123K
- Hong VoChicago$91K
- Asokumar BuvanendranChicago$52K
- Ramsin BenyaminBloomington$32K
- Adam YoungChicago$29K
- Salman SagarwalaChicago$26K
- Jay JoshiDeer Park$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.